Page 103 - 2021年14期

and partitioned survival model lead to different results：a [20] CADTH. Procedures for the CADTH pan-Canadian onco-
review of recent economic evidence of cancer treat- logy drug review[EB/OL].（2015-05-05）[2020-09-04].
ments[J]. Expert Rev Pharmacoecon Outcomes Res，2021， https：//www.cadth.ca/sites/default/files/pcodr/pCODR％
21（3）：373-380. 27s％ 20Drug％ 20Review％ 20Process/pcodr-procedures.
[ 9 ] 邵荣杰，唐文熙，马爱霞.分区生存模型在药物经济学评 pdf.
价中的应用[J].中国卫生经济，2019，38（9）：60-63. [21] CADTH. Arzerra for chronic lymphocytic leukemia：de-
[10] 徐赫，田磊，孟蕊，等.不同类型研究设计在卫生决策中的 tails[EB/OL].（2015-01-29）[2020-09-04]. https：//www.
应用情况[J].中国医院药学杂志，2020，40（18）：1905- cadth.ca/sites/default/files/pcodr/pcodr-arzerra-cll-fn-egr.
1909，1956. pdf.
[11] 周挺，李洪超，马爱霞，等.加拿大药品统一审评制度及价 [22] CADTH. Cabozantinib（Cabometyx）for hepatocellular car-
格管理体系简析[J].中国卫生经济，2018，37（2）：94-96. cinoma[EB/OL].（2020-04-22）[2021-06-30]. https：//www.
[12] BULLEMENT A，CRANMER H L，SHIELDS G E. A cadth.ca/sites/default/files/pcodr/Reviews2020/10186Ca-
review of recent decision-analytic models used to evaluate bozantinibHCC_fnEGR_NOREDACT-ABBREV_EC_22-
the economic value of cancer treatments[J]. Appl Health Apr2020_final.pdf.
Econ Health Policy，2019，17（6）：771-780. [23] SONG F，LOKE Y K，WALSH T，et al. Methodological
[13] WOODS B S，SIDERIS E，PALMER S J，et al. NICE problems in the use of indirect comparisons for evaluating
DSU technical support document 19：partitioned survival healthcare interventions：survey of published systematic
analysis for decision modelling in health care：a critical re- reviews[J]. BMJ，2009，338：b1147.
view [EB/OL].（2017-06-02）[2021-06-30]. http：//nicedsu. [24] 刘新义，谭重庆，曾小慧，等.分区生存模型在药物经济学
org.uk/wp-content/uploads/2017/06/Partitioned-Survival- 评价中的应用简介及实例解析[J].中国现代应用药学，
Analysis-final-report.pdf. 2019，36（24）：3090-3093.
[14] RUI M，SHI F，SHANG Y，et al. Economic evaluation of [25] 曾小慧，彭六保，谭重庆，等.药物经济学评价中的分区生
cisplatin plus gemcitabine versus paclitaxel plus gem- 存模型[J].中国新药与临床杂志，2020，39（8）：504-507.
citabine for the treatment of first-line advanced metastatic [26] 徐赫，马爱霞.基于分区生存模型的帕博利珠单抗单药与
triple-negative breast cancer in China：using Markov mo- 化疗一线治疗 PD-L1 肿瘤比例分数不同的非小细胞肺
del and partitioned survival model[J]. Adv Ther，2020，37 癌的成本-效果分析[J].中国医院药学杂志，2020，40
（9）：3761-3774. （23）：2468-2473.
[15] SMARE C，LAKHDARI K，DOAN J，et al. Evaluating [27] RUI M，LI H. Cost-effectiveness of osimertinib vs doce-
partitioned survival and Markov decision-analytic mode- taxel-bevacizumab in third-line treatment in EGFR T790M
ling approaches for use in cost-effectiveness analysis：esti- resistance mutation advanced non-small cell lung cancer
mating and comparing survival outcomes[J]. Pharmaco- in China[J]. Clin Ther，2020，42（11）：2159-2170.
economics，2020，38（1）：97-108. [28] GIBSON E J，BEGUM N，KOBLBAUER I，et al. Mode-
[16] BULLEMENT A，LATIMER N R，BELL GORROD H. ling the economic outcomes of immuno-oncology drugs：
Survival extrapolation in cancer immunotherapy：a valida- alternative model frameworks to capture clinical out-
tion-based case study[J]. Value Health，2019，22（3）：276- comes[J]. Clinicoecon Outcomes Res，2018，10：139-154.
283. [29] 田磊，赵昕锐，李洪超.我国肿瘤免疫治疗经济学评价研
[17] WILLIAMS C，LEWSEY J D，MACKAY D F，et al. Es- 究现状与挑战[J].卫生经济研究，2021，38（1）：35-39.
timation of survival probabilities for use in cost-effective- [30] CARO J J，BRIGGS A H，SIEBERT U，et al. ISPOR-
ness analyses：a comparison of a multi-state modeling sur- SMDM modeling good research practices task force：mo-
vival analysis approach with partitioned survival and Mar- deling good research practices：overview：a report of the
kov decision-analytic modeling[J]. Med Decis Making， ISPOR-SMDM modeling good research practices task
2017，37（4）：427-439. force-1[J]. Med Decis Making，2012，32（5）：667-677.
[18] SIEBERT U，ALAGOZ O，BAYOUMI A M，et al. ISPOR- [31] BRIGGS A H，WEINSTEIN M C，FENWICK E A，et al.
SMDM modeling good research practices task force. ISPOR-SMDM modeling good research practices task
State-transition modeling：a report of the ISPOR-SMDM force：model parameter estimation and uncertainty analy-
modeling good research practices task force-3[J]. Value sis：a report of the ISPOR-SMDM modeling good re-
Health，2012，15（6）：812-820. search practices task force working group-6[J]. Med Decis
[19] 周挺，马爱霞，付露阳.药物经济学评价Markov模型中转 Making，2012，32（5）：722-732.
移概率计算的探讨[J].中国卫生经济，2017，36（12）：40- （收稿日期：2021-01-20 修回日期：2021-06-30）
42. （编辑：孙 冰）

中国药房 2021年第32卷第14期 China Pharmacy 2021 Vol. 32 No. 14 ·1757 ·